Academic Journal
Efficacy of l‐Arginine treatment in patients with HTLV‐1‐associated neurological disease
| العنوان: | Efficacy of l‐Arginine treatment in patients with HTLV‐1‐associated neurological disease |
|---|---|
| المؤلفون: | Satoshi Nozuma, Eiji Matsuura, Yuichi Tashiro, Ryusei Nagata, Masahiro Ando, Yu Hiramatsu, Yujiro Higuchi, Yusuke Sakiyama, Akihiro Hashiguchi, Kumiko Michizono, Keiko Higashi, Toshio Matsuzaki, Daisuke Kodama, Masakazu Tanaka, Yoshihisa Yamano, Takashi Moritoyo, Ryuji Kubota, Hiroshi Takashima |
| المصدر: | Annals of Clinical and Translational Neurology, Vol 10, Iss 2, Pp 237-245 (2023) |
| بيانات النشر: | Wiley, 2023. |
| سنة النشر: | 2023 |
| المجموعة: | LCC:Neurosciences. Biological psychiatry. Neuropsychiatry LCC:Neurology. Diseases of the nervous system |
| مصطلحات موضوعية: | Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429 |
| الوصف: | Abstract Objective HTLV‐1 infection causes HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), resulting in loss of motor function. In this Phase 2 trial, we assessed the efficacy and safety of l‐arginine in patients with HAM/TSP. Methods This open‐label, single‐arm, Phase 2 study enrolled patients diagnosed with HAM/TSP. Patients received l‐arginine at a dose of 20 g orally for 1 week and were followed‐up for 3 weeks. The primary endpoint was change in walking speed in the 10‐m walk test (10MWT). The main secondary endpoints were change in Timed Up and Go Test (TUGT) time, improvement in inflammatory markers in cerebrospinal fluid (CSF), safety, and tolerability. Results The study enrolled 20 patients (13 [65%] female) with a mean age of 67.8 years (95% CI 62.3 to 73.3). Although the primary endpoint, the changes in 10MWT time between baseline (Day 0) and Day 7, did not reach statistical significance (mean percent change in time −3.5%, 95% CI −10.8% to 3.7%; P = 0.32), a significant improvement was detected between baseline and Day 14 (−9.4%, 95% CI −16.6% to −2.2%; P = 0.01). Significant improvements were also observed in selected secondary endpoints, including in TUGT time (−9.1%, 95% CI −15.5% to −2.7%; P |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2328-9503 |
| Relation: | https://doaj.org/toc/2328-9503 |
| DOI: | 10.1002/acn3.51715 |
| URL الوصول: | https://doaj.org/article/2f465b03ac204e548d2aa22e4626964f |
| رقم الانضمام: | edsdoj.2f465b03ac204e548d2aa22e4626964f |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 23289503 |
|---|---|
| DOI: | 10.1002/acn3.51715 |